Description of studies using visual method for iPET interpretation
| References . | DLBCL pts (n) . | Median age . | Type of study . | Treatment . | Nb of cycles of chemotherapy before iTEP . | iPET analysis method . | iPET driven . |
|---|---|---|---|---|---|---|---|
| Jerusalem et al30 | 16 out of 28 | 61 | Monocentric retrospective | Various without rituximab | From 2 to 5 | Local visual | No |
| Spaepen et al8 | 47 out of 70 | 50 | Monocentric retrospective | Various without rituximab | 3 (n = 36) or 4 (n = 34) | Local visual | No |
| Mikhaeel et al40 | 63 out of 121 | 55 | Monocentric retrospective | Mostly CHOP ± rituximab | 2 (n = 85) or 3 (n = 36) | Local visual 3-score scale (negative, MRU, positive) | No |
| Kostakoglu et al5 | 24 out of 47 | 63 | Monocentric retrospective | CHOP × 6 or 8 ± rituximab | 1 | Local visual and semiquantitative | No |
| Querellou et al41 | 23 out of 48 | 55 | Monocentric retrospective | Mostly R-CHOP or R-CHOP-like | 2 or 3 or 4 | Local visual | No |
| Han et al9 | 38 out of 51 | 59 | Monocentric retrospective | R-CHOP-21 × 6 or 8 | 2 or 3 or 4 | Local visual | No |
| Fruchard et al42 | 35 out of 40 | 56 | Monocentric retrospective | CHOP or CHOP-like rituximab | 2 or 3 | Local visual | No |
| Dupuis et al39 | 103 | 53 | Multicentric prospective | CHOP or CHOP-like ± rituximab | 4 | Local visual | No |
| Moskowitz et al11 | 98 GC = 37; nGC = 28; PMBCL = 28 | 47 pts < 65 y | Monocentric retrospective | R-CHOP-14 × 4 plus 3 × ICE if iPETneg and iPET+ without DLBCL in biopsy or ICE × 2/R-ICE/ASCT if iPET+ with DLBCL biopsy | 4 | Local visual ΔSUV only exploratory | Yes |
| Cashen et al15 | 52 | 58 | Monocentric retrospective | R-CHOP-21 × 6 | 2 | Local (with retrospective review) visual | No |
| Yang et al45 | 161 | 61 | Monocentric prospective | R-CHOP-21 × 6 or 8 | 3 (48.4%) or 4 (50.3%) | Local and retrospective review (Cheson 2007 plus D5S) | No |
| Micallef et al46 | 107 | 62 | Multicentric prospective | R-CHOP-21 plus Epratuzumab | 2 | Central visual | No |
| Zinzani et al47 | 91; PMBCL = 13 | 54 | Monocentric retrospective | R-CHOP or R-CHOP-like | Various | Local visual | No |
| Yoo et al48 | 155 | 56 | Retrospective national database | R-CHOP | 2 (5%) or 3 (52%) or 4 (43%) | Local visual | No |
| Safar et al22 | 112 | 59 | Multicentric prospective | R-CHOP or R-ACVBP | 2 | Local visual ΔSUV exploratory | No |
| Carr et al44 | 327 | 55 | Multicentric prospective | R-CHOP-21 (6 or 8 cycles) | 2 (77%) or 3 (22%) | Central visual | No |
| Swinnen et al49 | 80 | 62 | Multicentric prospective | R-CHOP × 4 and R-ICE if iPETpos or R-CHOP × 2 if iPETneg | 3 | Central visual 4 scales | Yes |
| Mamot et al23 | 138 GC: 34% or non-GC: 66% | 58.4 | Multicentric prospective and retrospective | R-CHOP-14 × 6 | 2 and 4 | Local for visual (prospective) ΔSUV/Deauville (exploratory) | No |
| Hertzberg et al31 | 151 | 57 | Multicentric prospective | Dose-dense R-CHOP-14 × 4 followed by R-CHOP-14 × 2 if iPETneg or R-ICE plus ASCT if iPETpos | 4 | Central visual (IHP) | Yes |
| References . | DLBCL pts (n) . | Median age . | Type of study . | Treatment . | Nb of cycles of chemotherapy before iTEP . | iPET analysis method . | iPET driven . |
|---|---|---|---|---|---|---|---|
| Jerusalem et al30 | 16 out of 28 | 61 | Monocentric retrospective | Various without rituximab | From 2 to 5 | Local visual | No |
| Spaepen et al8 | 47 out of 70 | 50 | Monocentric retrospective | Various without rituximab | 3 (n = 36) or 4 (n = 34) | Local visual | No |
| Mikhaeel et al40 | 63 out of 121 | 55 | Monocentric retrospective | Mostly CHOP ± rituximab | 2 (n = 85) or 3 (n = 36) | Local visual 3-score scale (negative, MRU, positive) | No |
| Kostakoglu et al5 | 24 out of 47 | 63 | Monocentric retrospective | CHOP × 6 or 8 ± rituximab | 1 | Local visual and semiquantitative | No |
| Querellou et al41 | 23 out of 48 | 55 | Monocentric retrospective | Mostly R-CHOP or R-CHOP-like | 2 or 3 or 4 | Local visual | No |
| Han et al9 | 38 out of 51 | 59 | Monocentric retrospective | R-CHOP-21 × 6 or 8 | 2 or 3 or 4 | Local visual | No |
| Fruchard et al42 | 35 out of 40 | 56 | Monocentric retrospective | CHOP or CHOP-like rituximab | 2 or 3 | Local visual | No |
| Dupuis et al39 | 103 | 53 | Multicentric prospective | CHOP or CHOP-like ± rituximab | 4 | Local visual | No |
| Moskowitz et al11 | 98 GC = 37; nGC = 28; PMBCL = 28 | 47 pts < 65 y | Monocentric retrospective | R-CHOP-14 × 4 plus 3 × ICE if iPETneg and iPET+ without DLBCL in biopsy or ICE × 2/R-ICE/ASCT if iPET+ with DLBCL biopsy | 4 | Local visual ΔSUV only exploratory | Yes |
| Cashen et al15 | 52 | 58 | Monocentric retrospective | R-CHOP-21 × 6 | 2 | Local (with retrospective review) visual | No |
| Yang et al45 | 161 | 61 | Monocentric prospective | R-CHOP-21 × 6 or 8 | 3 (48.4%) or 4 (50.3%) | Local and retrospective review (Cheson 2007 plus D5S) | No |
| Micallef et al46 | 107 | 62 | Multicentric prospective | R-CHOP-21 plus Epratuzumab | 2 | Central visual | No |
| Zinzani et al47 | 91; PMBCL = 13 | 54 | Monocentric retrospective | R-CHOP or R-CHOP-like | Various | Local visual | No |
| Yoo et al48 | 155 | 56 | Retrospective national database | R-CHOP | 2 (5%) or 3 (52%) or 4 (43%) | Local visual | No |
| Safar et al22 | 112 | 59 | Multicentric prospective | R-CHOP or R-ACVBP | 2 | Local visual ΔSUV exploratory | No |
| Carr et al44 | 327 | 55 | Multicentric prospective | R-CHOP-21 (6 or 8 cycles) | 2 (77%) or 3 (22%) | Central visual | No |
| Swinnen et al49 | 80 | 62 | Multicentric prospective | R-CHOP × 4 and R-ICE if iPETpos or R-CHOP × 2 if iPETneg | 3 | Central visual 4 scales | Yes |
| Mamot et al23 | 138 GC: 34% or non-GC: 66% | 58.4 | Multicentric prospective and retrospective | R-CHOP-14 × 6 | 2 and 4 | Local for visual (prospective) ΔSUV/Deauville (exploratory) | No |
| Hertzberg et al31 | 151 | 57 | Multicentric prospective | Dose-dense R-CHOP-14 × 4 followed by R-CHOP-14 × 2 if iPETneg or R-ICE plus ASCT if iPETpos | 4 | Central visual (IHP) | Yes |
ACVBP, adriamycine, cyclophosphamide, vinblastine, bleomycine, and prednisolone; D5S, Deauville 5 scales; GC, germinal center; MRU, minimal residual uptake; nb, number; neg, negative; PMBCL, primary mediastinal B-cell lymphoma; pos, positive; pts, patients; ΔSUV, Δ SUV method (see article).